华东医药：全资子公司华东医药杭州与江苏威凯尔签署独家商业化合作协议

Core Viewpoint - East China Pharmaceutical announced an exclusive commercialization agreement with Jiangsu Weikail, acquiring exclusive commercialization rights for the oral formulation VC005 in mainland China [1] Group 1: Agreement Details - East China Pharmaceutical's subsidiary, East China Pharmaceutical Hangzhou, will pay an upfront fee of 50 million RMB and up to 180 million RMB in milestone payments for registration [1] - VC005 is a novel, potent, and highly selective second-generation oral JAK1 inhibitor, currently in Phase III clinical trials for moderate to severe atopic dermatitis [1]